SCHEMBL8038019

SCHEMBL8038019

Cc1cc(CN2CCN(C)CC2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.51
CHKA P35790 6/20 0.50
LMNA P02545 1/20 0.49
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
CA2 P00918 1/20 0.44
NCF1 P14598 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
MAPT P10636 1/20 0.44
IKBKE Q14164 1/20 0.43
TBK1 Q9UHD2 1/20 0.43
NPC1 O15118 2/20 0.43
TP53 P04637 2/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 1/20 0.42
METAP2 P50579 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21158864 0.87 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTNPC1TP53
SCHEMBL4553879 0.86 CXCR4 (0.50) CHKAALDH1A1PRMT6
SCHEMBL20148586 0.83 ALDH1A1 (0.49) ALDH1A1KDM4E
SCHEMBL24027019 0.82 LMNA (0.56) MC4RCHKALMNAALDH1A1KDM4E
SCHEMBL12650851 0.82 MC4R (0.50) MC4RCHKALMNAALDH1A1KDM4E
SCHEMBL2933524 0.82 MC4R (0.50) MC4RCHKALMNAALDH1A1KDM4E
SCHEMBL12241723 0.82 HRH3 (0.50) ALDH1A1KDM4ENCF1MAPTNPC1
SCHEMBL17331777 0.82 MC4R (0.54) MC4RCHKALMNAALDH1A1KDM4E
SCHEMBL15214329 0.81 ACHE (0.54) ALDH1A1
SCHEMBL12606991 0.81 ALDH1A1 (0.53) MC4RCHKALMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
US-9637492-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2017-05-02 US disclosed
WO-2015193263-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-23 WO disclosed
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use INTELLIKINE LLC 2015-08-13 US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 US disclosed
US-8637542-B2 Kinase inhibitors and methods of use INTELLIKINE, INC. (US) 2014-01-28 US disclosed
WO-2009114870-A2 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use MTOR, PDPK1, PIKFYVE MC4R 1375/4885CHKA 480/4885LMNA 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.